Eventide Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Eventide Asset Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,227,376	Closed	-$91.8M	–	167
2021 Q3	$91.8M	Sell	5,227,376 -4,282,624	-45%	-$50M	1.21%	28
2021 Q2	$92.2M	Buy	9,510,000 +1,851,000	+24%	+$17.4M	1.24%	29
2021 Q1	$82.3M	Buy	7,659,000 +2,877,552	+60%	+$35.6M	1.22%	28
2020 Q4	$70.3M	Buy	4,781,448 +1,584,440	+50%	+$22.8M	1.08%	31
2020 Q3	$45.4M	Buy	3,197,008 +650,008	+26%	+$6.48M	0.89%	38
2020 Q2	$20.6M	Buy	+2,547,000	New	+$15.8M	0.45%	68

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Eventide Asset Management's TRIL Position: Q4 2021 in Review

Eventide Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 5,227,376 shares — an estimated $91.8M sold.

Eventide Asset Management first reported a position in TRIL in Q2 2020 and held it in 6 quarters. The position peaked at $92.2M in Q2 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Eventide Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Eventide Asset Management sold 5,227,376 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $91.8M.
Eventide Asset Management first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 6 quarters.
Eventide Asset Management's Trillium Therapeutics Inc. position peaked at $92.2M in Q2 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Eventide Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.